Heart Benefits From GLP-1 Drugs Fade After Stopping, Study Finds
Medically reviewed by Drugs.com
via HealthDayFRIDAY, March 20, 2026 — Drugs like Ozempic and Mounjaro are known to lower the risk of heart attack and stroke, but a new study suggests those benefits may not last if people stop taking them.
Researchers found that heart risks begin to rise again within six months after stopping GLP-1 medications, and much of the benefit may be gone within about 18 months.
"It takes a whole lot longer to build or accrue benefit, and then half as much to erase all that benefit," study author Dr. Ziyad Al-Aly, a clinical epidemiologist at Washington University in St. Louis, told CNN.
“For example, what took three years to build — three years of the cardiovascular benefit — was actually erased or undone with just one and a half years of stopping," he added.
The study — published March 18 in BMJ Medicine — reviewed medical records from more than 333,000 people with type 2 diabetes treated through the Veterans Health Administration.
Researchers compared about 132,000 patients who took GLP-1 drugs with more than 201,000 who used older diabetes drugs called sulfonylureas.
The GLP-1 group included people taking medications such as semaglutide (Ozempic), tirzepatide (Mounjaro), and older drugs like liraglutide (Victoza) and dulaglutide (Trulicity).
People who stayed on GLP-1 drugs for about three years had the biggest benefit. Their risk of heart attack, stroke or death was about 18% lower than those taking other medications.
Researchers also tracked what happened when people stopped taking GLP-1 drugs. Compared to those who stayed on treatment, their:
By that point, the earlier heart benefits were nearly gone.
The researchers described the effect as "metabolic whiplash," where the body quickly loses the gains made during treatment.
Doctors say GLP-1 drugs help the heart in several ways. Many people lose weight on them, which lowers inflammation. But the drugs may also act directly on the heart.
Another large 2023 study, called SELECT, found a similar effect, showing about a 20% drop in heart events in people taking semaglutide.
Dr. Melanie Jay, an obesity expert at NYU Langone in New York City, said “it means there’s weight dependent and weight independent effects on the heart."
About half of people who start GLP-1 drugs stop within a year, often due to side effects like nausea or because of the cost.
“This is something you likely need for a longer, long period of time, chronic basis,” Al-Aly said.
He added that insurance coverage can be a barrier, especially for folks who lose coverage after reaching their weight loss goals.
“Stopping has consequences to the heart,” Al-Aly said. “Insurers need to realize that, you know, when they deny these things that actually exposing people to unnecessary risk.”
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-21 01:42
Read more
- SMFM: Prenatal COVID-19 Vaccine Does Not Impact Neurodevelopmental Outcomes in Offspring
- Clinical Trial Results Support Use of Weekly Extended-Release Buprenorphine for Treatment of Opioid Use Disorder During Pregnancy
- ACC: Higher Ultraprocessed Food Consumption Tied to Increased Risk for Atherosclerotic CVD
- Blood Test Can Predict Short-Term Survival Among Seniors
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions